New hope for advanced cervical cancer: drug duo takes on chemo
NCT ID NCT04906993
First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 31 times
Summary
This phase 3 study tests whether a combination of two drugs (camrelizumab and famitinib) works better than standard chemotherapy for women with cervical cancer that has returned or spread. About 443 women who have not had prior treatment for advanced disease will be randomly assigned to one of the two groups. The main goals are to see if the new combo helps women live longer without their cancer growing and to check safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.